Core Viewpoint - The ongoing legal dispute involving Aikang Guobin and the allegations of failing to detect cancer during a decade of health check-ups has gained significant attention, with recent developments indicating a shift in jurisdiction to the Beijing Internet Court [1][3]. Group 1: Legal Developments - Zhang Xiaoling received a civil ruling from the Shanghai Pudong New District People's Court, which stated that her objection to jurisdiction was valid, and the case should be handled by the Beijing Internet Court [1][3]. - Aikang Guobin filed a lawsuit against Zhang Xiaoling, claiming her statements about "fake health checks" and failure to detect cancer infringed on the company's reputation [2][3]. - The court's ruling indicated that the case's relevant parties and actions were primarily based in Beijing, justifying the transfer of jurisdiction [3]. Group 2: Allegations and Responses - Zhang Xiaoling alleged that Aikang Guobin failed to detect her kidney cancer risk over ten years of check-ups, leading to a late-stage diagnosis in 2024 [5][6]. - Aikang Guobin responded by asserting that there is no recognized early diagnostic marker for kidney cancer, disputing the claims of misdiagnosis or negligence [6][7]. - The company emphasized that the 2023 health report did indicate potential issues, suggesting that the cancer could develop undetectably over time [7]. Group 3: Industry Implications - The incident has raised concerns about the accuracy and reliability of health check-ups, prompting discussions on how to enhance public trust in health screening services [9][10]. - Experts suggest that personalized health check-ups tailored to individual risk factors could improve detection rates and overall service quality in the industry [9][10]. - Legal experts indicate that the outcome of this case may clarify the responsibilities and obligations of health check-up institutions, potentially leading to stricter regulations and standards within the industry [11].

Core Viewpoint - The incident involving a woman diagnosed with late-stage cancer after ten years of normal health check-ups raises significant concerns about the accuracy and reliability of health screening services provided by Aikang Group [1][3][4]. Company Response - Aikang Group stated that some cancers can be detected while others cannot, emphasizing that the health check reports accurately reflect the results at the time of examination [1][3]. - The company plans to engage third-party authoritative institutions and experts to analyze the reasons behind the undetected cancer cases, with the final conclusions based on their recommendations [1][3][5]. Health Screening Findings - The woman had normal cancer marker levels (carcinoembryonic antigen) throughout her ten years of check-ups at Aikang, with no alerts regarding cancer risks for her kidneys or spine [4][5]. - In 2024, after switching to a different health screening provider, a cyst measuring 3.5cm x 2.8cm was discovered in her right kidney, which was later diagnosed as renal cell carcinoma [4][5]. Industry Implications - The incident has sparked discussions within the health screening industry regarding the limitations of detection technologies and the varying levels of professional expertise among practitioners [6]. - It highlights the need for continuous updates in detection equipment and technology, as well as improved training and management for healthcare professionals [6]. Legal Considerations - Legal experts suggest that the key issue is whether Aikang Group fulfilled its diagnostic obligations according to the medical standards at the time of the examinations [7]. - If it is determined that necessary checks were not performed, it could lead to claims of misdiagnosis or missed diagnosis, potentially resulting in liability for Aikang Group [7].